Compare · EYE vs STAA
EYE vs STAA
Side-by-side comparison of National Vision Holdings Inc. (EYE) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EYE and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- STAA is the larger of the two at $1.49B, about 1.2x EYE ($1.24B).
- Over the past year, EYE is down 23.8% and STAA is up 76.3% - STAA leads by 100.0 points.
- STAA has been more active in the news (4 items in the past 4 weeks vs 2 for EYE).
- STAA has more recent analyst coverage (25 ratings vs 20 for EYE).
- Company
- National Vision Holdings Inc.
- STAAR Surgical Company
- Price
- $16.02+3.72%
- $30.25+0.77%
- Market cap
- $1.24B
- $1.49B
- 1M return
- -29.81%
- +10.89%
- 1Y return
- -23.76%
- +76.28%
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 2
- 4
- Recent ratings
- 20
- 25
National Vision Holdings Inc.
National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. As of January 2, 2021, the company operated through 1,205 retail stores, as well as various e-commerce websites. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest EYE
- National Vision Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- National Vision, Inc. Announces Participation in William Blair 46th Annual Growth Stock Conference
- SEC Form 10-Q filed by National Vision Holdings Inc.
- National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- National Vision Holdings, Inc. Reports First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by National Vision Holdings Inc.
- SEC Form DEF 14A filed by National Vision Holdings Inc.
- Chief Legal & Strategy Officer Brandman Jared converted options into 1,890 shares and covered exercise/tax liability with 842 shares, increasing direct ownership by 1% to 77,079 units (SEC Form 4)
- SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.
- National Vision Holdings, Inc. Announces First Quarter 2026 Earnings Release and Conference Call
Latest STAA
- STAAR Surgical Announces Participation in Upcoming Investor Conferences
- Chief Development Officer Michna Magda was granted 19,795 shares and covered exercise/tax liability with 9,703 shares, increasing direct ownership by 31% to 42,783 units (SEC Form 4)
- Interim Co-CEO and CFO Andrews Deborah J was granted 15,699 shares and covered exercise/tax liability with 5,632 shares (SEC Form 4)
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 16,785 shares and was granted 32,990 shares, increasing direct ownership by 24% to 83,112 units (SEC Form 4)
- STAAR Surgical upgraded by Wedbush with a new price target
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports First Quarter 2026 Results; Issues Shareholder Letter
- Interim Co-CEO and Pres. & COO Foust Warren covered exercise/tax liability with 3,448 shares, decreasing direct ownership by 5% to 66,917 units (SEC Form 4)
- Chief Development Officer Michna Magda covered exercise/tax liability with 1,680 shares, decreasing direct ownership by 5% to 32,691 units (SEC Form 4)